Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
EPHA7 Biologics Sequence Review Report 2026: Ephrin type-A receptor 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA6 Biologics Sequence Review Report 2026: Ephrin type-A receptor 6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA3 Biologics Sequence Review Report 2026: Ephrin type-A receptor 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA2 Biologics Sequence Review Report 2026: Ephrin type-A receptor 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA4 Biologics Sequence Review Report 2026: Ephrin type-A receptor 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA5 Biologics Sequence Review Report 2026: Ephrin type-A receptor 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA1 Biologics Sequence Review Report 2026: Ephrin type-A receptor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS5 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA10 Biologics Sequence Review Report 2026: Ephrin type-A receptor 10 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS6 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS3 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS19 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.